1. "Executive Committee, Center for Hematologic Malignancies"
  2. "Dermatology Service"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (11)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (29)
  2. Department of Medicine (29)
  3. Dermatology (29)
  4. Dermatology Service (29)
  5. Division of Subspecialty Medicine (29)
  6. Executive Committee, Center for Hematologic Malignancies (29)

More Groups

People
  1. Mario Lacouture (23)
  2. Omar Abdel-Wahab (22)
  3. Eli Diamond (18)
  4. Benjamin Durham (16)
  5. David Hyman (11)
  6. Raajit Rampal (10)

More People

Years
  1. 2023 (5)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (2)
  6. 2018 (3)

More Years

Publications
  1. Blood (10)
  2. Pediatric Blood and Cancer (4)
  3. Journal of Clinical Oncology (3)
  4. British Journal of Haematology (2)
  5. Cancer Discovery (2)
  6. Blood Advances (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Nature Publishing Group (4)
  3. Wiley Periodicals, Inc (4)
  4. American Society of Clinical Oncology (3)
  5. American Association for Cancer Research (2)
  6. John Wiley & Sons (2)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes with MEK inhibitor therapy among adults with Langerhans cell histiocytosis (LCH): A multi-institutional study from the Adult LCH Working Group for the Histiocyte Society
    Meeting Abstract

    Goyal, G.; Acosta Medina, A. A.; Cao, X.; Bossert, D.; Matthew, P. C.; Makras, P.; Abdel-Wahab, O.; Abeykoon, J. P.; Amerikanou, R.; Bach, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms
    Meeting Abstract

    Diamond, E. L.; Durham, B.; Dogan, A.; Yabe, M.; Petrova-Drus, K.; Rampal, R. K.; Ulaner, G.; Lacouture, M.; Rotemberg, V.; Covey, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • ETV6-FLT3–positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: An entity distinct from JMML
    Journal Article

    Spitzer, B.; Dela Cruz, F. S.; Ibanez Sanchez, G. D.; Zhang, Y.; Xiao, W.; Benayed, R.; Markova, A.; Rodriguez-Sanchez, M. I.; Bouvier, N.; Roshal, M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features
    Research Letter

    Argyropoulos, K. V.; Pulitzer, M.; Maura, F.; Mohanty, A.; Mondello, P.; Horwitz, S. M.; Myskowski, P.; Moskowitz, A.; Dogan, A.; Querfeld, C.; more...
    Blood Cancer Journal (2020)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Novel alterations in CSF1R, RET, and other diverse kinases in the histiocytoses with biochemical and structural insights into their mechanisms of activation
    Meeting Abstract

    Durham, B.; Lopez-Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S.; Pastore, A.; Mandelker, D.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save